Offers Claimed: 95
Downloaded Today: 58
USARx offers the following ways to purchase this medication. Choose the Best option for you!
NoIn general, Medicare plans do not cover this drug. This drug will likely be quite expensive and you may want to consider using a USARx discount instead of Medicare to find the best price for this prescription.
It depends. Which coverage stage are you in? Click on a tab below…
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your contrave prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Note: This document contains side effect information about bupropion / naltrexone. Some of the dosage forms listed on this page may not apply to the brand name Contrave.In Summary
Common side effects of Contrave include: constipation, dizziness, headache, insomnia, nausea, and vomiting. Other side effects include: anxiety, diarrhea, increased blood pressure, tremor, depression, hypertension, and xerostomia. See below for a comprehensive list of adverse effects.For the Consumer
Applies to bupropion / naltrexone: oral tablet extended release
Oral route (Tablet, Extended Release)
Naltrexone hydrochloride/buPROPion hydrochloride is not approved for use in the treatment of major depressant disorder or other psychiatric disorders. Naltrexone hydrochloride/buPROPion hydrochloride contains buPROPion, the same active ingredient as some other antidepressant medications (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, and Aplenzin). Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older. In patients of all ages who are started on naltrexone hydrochloride/buPROPion hydrochloride, monitor closely for worsening, and for the emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. Naltrexone hydrochloride/buPROPion hydrochloride is not approved for use in pediatric patients.
Along with its needed effects, bupropion / naltrexone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking bupropion / naltrexone:
Less common or rare
Incidence not known
Get emergency help immediately if any of the following symptoms of overdose occur while taking bupropion / naltrexone:
Symptoms of overdose
Some side effects of bupropion / naltrexone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common or rare
For Healthcare Professionals
Applies to bupropion / naltrexone: oral tablet extended releaseGeneral
The more commonly reported adverse reactions have included nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea.Psychiatric
Very common (10% or more): Sleep disorders (up to 13.8%)
Common (1% to 10%): Depression, anxiety, irritability
Uncommon (0.1% to 1%): Insomnia, abnormal dreams, nervousness, dissociation (feeling spacey), tension, agitation, mood swings
Rare (less than 0.1%): Suicidal ideation
During clinical trials, suicidal ideation was reported by 0.03% (n=1/3239) of patients receiving this drug and 0.2% of placebo (n=3/1239) patients. No suicides or suicide attempts were reported in studies up to 56 weeks.Nervous system
Very common (10% or more): Headache (up to 17.6%), dizziness (up to 10.4%)
Common (1% to 10%): Tremor, dysgeusia, attention disorders
Uncommon (0.1% to 1%): Vertigo, motion sickness, disturbance in attention, lethargy, intention tremor, balance disorder, memory impairment, amnesia, mental impairment, presyncope/syncope, hernia, seizure
Postmarketing reports: Loss of consciousness
The incidence of seizure in patients receiving this drug in clinical trials was approximately 0.1% vs 0% on placebo.Cardiovascular
Common (1% to 10%): Hot flush, hypertension, increased blood pressure, palpitations
Uncommon (0.1% to 1%): Tachycardia, myocardial infarction
Frequency not reported: Increased heart rate
During clinical trials, patients receiving this drug had increases to mean systolic and diastolic blood pressure (BP) of approximately 1 mmHg from baseline at weeks 4 and 8, BP similar to baseline at week 12, and BP approximately 1 mmHg below baseline between weeks 24 and 56. In contrast, mean BP for placebo treated patients was approximately 2 to 3 mmHg below baseline throughout the study. Mean heart rate was 2.1 beats per minute higher in the drug-treated patients at weeks 4 and 8; at week 52, the difference between groups was 1.7 beats per minute.Hypersensitivity
Frequency not reported: Anaphylactoid/anaphylactic reactions, symptoms suggestive of delayed hypersensitivity such as arthralgia, myalgia, fever with rash
Postmarketing reports: Erythema multiforme, Stevens-Johnson syndrome, and anaphylactic shockHepatic
Uncommon (0.1% to 1%): Cholecystitis, increased hepatic enzymesRenal
Serum creatinine increases that exceeded the upper limit of normal and were also 50% higher than baseline or greater occurred in 0.6% of patients receiving this drug (0.1% in placebo). The observed increase may be the result of OCT2 inhibition.
Uncommon (0.1% to 1%): Kidney infection, increased blood creatinine, increased serum creatinine, micturition urgencyDermatologic
Common (1% to 10%): Hyperhidrosis, rash
Uncommon (0.1% to 1%): AlopeciaGastrointestinal
Very common (10% or more): Nausea (up to 32.5%), constipation (up to 19.2%), vomiting (up to 10.7%)
Common (1% to 10%): Dry mouth, diarrhea, upper abdominal pain, viral gastroenteritis, abdominal pain
Uncommon (0.1% to 1%): Lower abdominal pain, eructation, lip swelling, hematocheziaGenitourinary
Common (1% to 10%): Urinary tract infection
Uncommon (0.1% to 1%): Vaginal hemorrhage, irregular menstruation, erectile dysfunction, vulvovaginal drynessHematologic
Uncommon (0.1% to 1%): Decreased hematocritImmunologic
Common (1% to 10%): InfluenzaMetabolic
Uncommon (0.1% to 1%): DehydrationMusculoskeletal
Common (1% to 10%): Muscle strain
Uncommon (0.1% to 1%): Intervertebral disc protrusion, jaw painOther
Common (1% to 10%): Fatigue, tinnitus
Uncommon (0.1% to 1%): Feeling jittery, feeling abnormal, asthenia, thirst, feeling hot, staphylococcal infection
Postmarketing reports: MalaiseRespiratory
Uncommon (0.1% to 1%): Pneumonia
March 3, 2021
June 23, 2016
May 9, 2021
March 31, 2021
March 29, 2021
March 27, 2021